NasdaqCM - Delayed Quote • USD
2.2200
+0.0800
+(3.74%)
At close: August 27 at 4:00:01 PM EDT
2.4100
+0.19
+(8.56%)
Pre-Market: 6:31:13 AM EDT
Chart Range Bar
Loading chart for NLSP
- Previous Close
2.1400 - Open
2.1400 - Bid 1.5900 x 200
- Ask 2.8100 x 200
- Day's Range
2.1400 - 2.2690 - 52 Week Range
1.3000 - 6.9600 - Volume
118,106 - Avg. Volume
253,258 - Market Cap (intraday)
10.896M - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.
--
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
More about NLS Pharmaceutics AG
Recent News: NLSP
View MorePerformance Overview: NLSP
Trailing total returns as of 8/27/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
NLSP
5.21%
S&P 500 (^GSPC)
10.20%
1-Year Return
NLSP
67.92%
S&P 500 (^GSPC)
15.21%
3-Year Return
NLSP
89.07%
S&P 500 (^GSPC)
59.73%
5-Year Return
NLSP
98.47%
S&P 500 (^GSPC)
86.00%
Compare To: NLSP
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
2.2200
+3.74%
Mkt Cap 10.896M
Industry Biotechnology
1.5100
-1.31%
Mkt Cap 30.443M
Industry Biotechnology
1.0700
+0.94%
Mkt Cap 5.325M
Industry Biotechnology
0.3019
0.00%
Mkt Cap 14.207M
Industry Biotechnology
1.4300
-7.74%
Mkt Cap 4.362M
Industry Biotechnology
2.9400
-4.85%
Mkt Cap 4.544M
Industry Biotechnology
1.3900
0.00%
Mkt Cap 7.616M
Industry Biotechnology
4.2600
+0.71%
Mkt Cap 2.277M
Industry Biotechnology
2,628.00
+1.74%
Mkt Cap ILA 110.21M
Industry Biotechnology
3.4200
0.00%
Mkt Cap 15.6M
Industry Biotechnology
13.32
-0.78%
Mkt Cap 64.207M
Industry Biotechnology
Statistics: NLSP
View More
Valuation Measures
As of 8/27/2025
Market Cap
10.90M
Enterprise Value
12.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-111.41%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.06M
Diluted EPS (ttm)
-2.6300
Balance Sheet and Cash Flow
Total Cash (mrq)
1.67M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.34M
Research Analysis: NLSP
View MoreCompany Insights: NLSP
Research Reports: NLSP
View MorePeople Also Watch
LIXT Lixte Biotechnology Holdings, Inc.
3.4200
0.00%
VRPX Virpax Pharmaceuticals, Inc.
0.0110
0.00%
ENTX Entera Bio Ltd.
1.9600
-1.01%
PRFX PainReform Ltd.
1.6100
-1.23%
ENSC Ensysce Biosciences, Inc.
2.0800
+0.97%
